The Annual General Shareholders' Meeting approved
the removal of non-competition restriction on the
newly-elected director.
Date of events
2022/05/24
To which item it meets
paragraph 21
Statement
1.Date of the shareholders' meeting resolution:2022/05/24
2.Name and title of the managerial officer with permission
to engage in competitive conduct:Lin, Yi-Fu, Director of the board
3.Items of competitive conduct in which the officer is
permitted to engage:
1.Independent Director of Taishin Holdings
2.Independent Director of Taishin Bank
3.Independent Director of Swissray Global Healthcare Holding Ltd.
4.Independent Director of Nanya Plastics
5.Independent Director of PAN German Universal Motors Ltd.
4.Period of permission to engage in the competitive conduct:During the
tenure of the director.
5.Circumstances of the resolution (please describe the
results of voting in accordance with Article 209 of the
Company Act):Total number of shares represented by attending shareholders:
251,642,039,
The number of voting for agreement:241,580,903,
The number of voting for disagreement:1,820,879,
The numner of invalid votes:0,
The number of votes abandoned and absence:8,240,257
96% of total number of shares represented by attending shareholders
approve the proposal.The proposal is approved upon voting.
6.If the permitted competitive conduct belongs to the
operator of a mainland China enterprise, the name and
title of the directors (if it is not the operator of
a mainland China enterprise, please enter "N/A" below):NA
7.Company name of the mainland China enterprise and the
officer's position in the enterprise:NA
8.Address of the mainland China enterprise:NA
9.Operations of the mainland China enterprise:NA
10.Impact on the company's finance and business:NA
11.If the directors have invested in the mainland China
enterprise, the monetary amount of the investment and
their shareholding ratio:NA
12.Any other matters that need to be specified:Lin, Yi-Fu has not
served as independent director of Swissray Global Healthcare Holding Ltd.
since April 29, 2022.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Oneness Biotech Co Ltd. published this content on 24 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 May 2022 11:28:05 UTC.
ONENESS BIOTECH CO., LTD. is a Taiwan-based company principally engaged in the research, development, production and sales of health products. The Company's main products include health supplies, health food and healthy food. The Company is also involved in the development of new drugs for the treatment of wound healing in chronic diabetic foot ulcers, as well as the development of new anticancer drugs. The Company distributes its products in domestic market.
ONENESS BIOTECH CO., LTD. 
